Skip to main content
Premium Trial:

Request an Annual Quote

Bad Times in the Bay Area

The drug discovery and development company Exelixis will be laying off 270 people, or 40 percent of its workforce, reports the San Francisco Business Times. The company's drug discovery group will bear the brunt of the cuts. The company says that having lower compensation, lab supplies and clinical trial costs will save it $90 million through 2011. "The Bay area biotech scene doesn't seem to be at its healthiest these days (although it's still in better shape than San Diego, from the sound of it), but this isn't going to help it one bit," adds Derek Lowe at In the Pipeline.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.